Shares of Sun Pharmaceutical Industries Ltd. 524715 inched up 0.08% to 1,785.30 Indian rupees Monday, on what proved to be an ...

Sun Pharmaceutical Industries Ltd. closed 12.97% below its 52-week high of 1,960.20 rupees, which the company achieved on ...

Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal.

Sun Pharmaceuticals Industries Ltd. on Monday, March 10, said it will acquire a Nasdaq-listed immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc.

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun Pharma’s oncology portfolio with FDA-approved UNLOXCYT for advanced cutaneous ...

The acquisition will be for an upfront cash payment of 4.10 dollars per share, aggregating up to 355 million dollars, the Sun Pharmaceutical Industries Ltd said on March 10. The deal, subject to ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a US-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal involves an upfront cash payment of $4.10 per share, totaling up ...

Sun Pharma is going to acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share, an official statement from the company revealed on Monday. The deal will come up to $355 million ...

(Reuters) -India’s Sun Pharmaceutical Industries said on Monday that it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, in a deal valued at up to $355 ...

Sun Pharma will acquire Checkpoint Therapeutics for $4.10 per share, with a potential additional $0.70 CVR. FDA-approved Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cSCC in ...